UNLV Expert: Vegas Leads Alzheimer’s Drug Breakthroughs.

UNLV’s 2026 pipeline review finds 192 trials and 158 drugs, a move beyond amyloid, and 29 Phase 2 readouts due in 2026.

Source: Las Vegas News